Clinical Cancer Research: 2 (6)

Cyclin D1 and estrogen receptor messenger RNA levels are positively correlated in primary breast cancer.

R Hui, A L Cornish, R A McClelland, J F Robertson, R W Blamey, E A Musgrove, R I Nicholson and R L Sutherland

Clin Cancer Res June 1 1996 2 (6) 923-928;
Telomerase activity in human bladder cancer.

Y Lin, H Miyamoto, K Fujinami, H Uemura, M Hosaka, Y Iwasaki and Y Kubota

Clin Cancer Res June 1 1996 2 (6) 929-932;
Positron emission tomography with 2-[18F]Fluoro-2-deoxy-D-glucose and 16alpha-[18F]fluoro-17beta-estradiol in breast cancer: correlation with estrogen receptor status and response to systemic therapy.

J E Mortimer, F Dehdashti, B A Siegel, J A Katzenellenbogen, P Fracasso and M J Welch

Clin Cancer Res June 1 1996 2 (6) 933-939;
Phase II study of 3-hour infusion of paclitaxel in previously untreated non-small cell lung cancer.

I Sekine, Y Nishiwaki, K Watanabe, S Yoneda and N Saijo

Clin Cancer Res June 1 1996 2 (6) 941-945;
Safety of autotransplants with high-dose melphalan in renal failure: a pharmacokinetic and toxicity study.

G Tricot, D S Alberts, C Johnson, D J Roe, R T Dorr, D Bracy, D H Vesole, S Jagannath, R Meyers and B Barlogie

Clin Cancer Res June 1 1996 2 (6) 947-952;
Murine and human in vivo penclomedine metabolism.

N R Hartman, S O'Reilly, E K Rowinsky, J M Collins and J M Strong

Clin Cancer Res June 1 1996 2 (6) 953-962;
Intrathecal 131I-labeled antitenascin monoclonal antibody 81C6 treatment of patients with leptomeningeal neoplasms or primary brain tumor resection cavities with subarachnoid communication: phase I trial results.

M T Brown, R E Coleman, A H Friedman, H S Friedman, R E McLendon, R Reiman, G J Felsberg, R D Tien, S H Bigner, M R Zalutsky, X G Zhao, C J Wikstrand, C N Pegram, J E Herndon 2nd, N A Vick, N Paleologos, R K Fredericks, S C Schold Jr and D D Bigner

Clin Cancer Res June 1 1996 2 (6) 963-972;
Retroviral transfer of the human MDR1 gene confers resistance to bisantrene-specific hematotoxicity.

I Aksentijevich, C O Cardarelli, I Pastan and M M Gottesman

Clin Cancer Res June 1 1996 2 (6) 973-980;
In vivo modulation of iododeoxyuridine metabolism and incorporation into cellular DNA by 5'-amino-5'-deoxythymidine in normal mouse tissues and two human colon cancer xenografts.

T J Kinsella, M C Glennon, K A Kunugi and M J Lindstrom

Clin Cancer Res June 1 1996 2 (6) 981-989;
Stimulation of cis-diamminedichloroplatinum(II) accumulation by modulation of passive permeability with genistein: an altered response in accumulation-defective resistant cells.

G Marverti and P A Andrews

Clin Cancer Res June 1 1996 2 (6) 991-999;
Cytolysis of tumor cells expressing the Neu/erbB-2, erbB-3, and erbB-4 receptors by genetically targeted naive T lymphocytes.

U Altenschmidt, R Kahl, D Moritz, B S Schnierle, B Gerstmayer, W Wels and B Groner

Clin Cancer Res June 1 1996 2 (6) 1001-1008;
Evaluation of transferrin and gallium-pyridoxal isonicotinoyl hydrazone as potential therapeutic agents to overcome lymphoid leukemic cell resistance to gallium nitrate.

C R Chitambar, P Boon and J P Wereley

Clin Cancer Res June 1 1996 2 (6) 1009-1015;
Inhibition of the growth of glioblastomas by CGP 41251, an inhibitor of protein kinase C, and by a phorbol ester tumor promoter.

M Begemann, S A Kashimawo, Y A Choi, S Kim, K M Christiansen, G Duigou, M Mueller, I Schieren, S Ghosh, D Fabbro, N M Lampen, D F Heitjan, P B Schiff, J N Bruce and I B Weinstein

Clin Cancer Res June 1 1996 2 (6) 1017-1030;
In vitro stimulation of erythropoiesis by stem cell factor alone in myelodysplastic syndrome patients with elevated endogenous erythropoietin serum levels.

H Zwierzina, T Bammer, I Rollinger-Holzinger, M Herold, P Fenaux, V Nüssler, E Hoflehner and D Geissler

Clin Cancer Res June 1 1996 2 (6) 1031-1038;
Characterization of a novel androgen-sensitive, prostate-specific antigen-producing prostatic carcinoma xenograft: LuCaP 23.

W J Ellis, R L Vessella, K R Buhler, F Bladou, L D True, S A Bigler, D Curtis and P H Lange

Clin Cancer Res June 1 1996 2 (6) 1039-1048;
Overexpression of the c-myc proto-oncogene in colorectal carcinoma is associated with a reduced mortality that is abrogated by point mutation of the p53 tumor suppressor gene.

D R Smith and H S Goh

Clin Cancer Res June 1 1996 2 (6) 1049-1053;
Predictive value of p53 mutations analyzed in bladder washings for progression of high-risk superficial bladder cancer.

J A Vet, J A Witjes, S A Marras, D Hessels, H G van der Poel, F M Debruyne and J A Schalken

Clin Cancer Res June 1 1996 2 (6) 1055-1061;
Relationship between platinum-DNA adducts in leukocytes of patients with advanced germ cell cancer and survival.

M J Fisch, K L Howard, L H Einhorn and G W Sledge

Clin Cancer Res June 1 1996 2 (6) 1063-1066;
Recurrence and death in non-small cell lung carcinomas: a prognostic model using pathological parameters, microvessel count, and gene protein products.

G Fontanini, S Vignati, D Bigini, A Mussi, M Lucchi, S Chiné, C A Angeletti and G Bevilacqua

Clin Cancer Res June 1 1996 2 (6) 1067-1075;
Expression of retinoic acid receptor beta in human renal cell carcinomas correlates with sensitivity to the antiproliferative effects of 13-cis-retinoic acid.

A D Hoffman, D Engelstein, T Bogenrieder, C N Papandreou, E Steckelman, A Dave, R J Motzer, E Dmitrovsky, A P Albino and D M Nanus

Clin Cancer Res June 1 1996 2 (6) 1077-1082;
Molecular staging of non-small cell lung cancer according to K-ras genotypes.

R Rosell, M Monzó, A Pifarré, A Ariza, J J Sánchez, I Moreno, J Maurel, M P López, A Abad and J M de Anta

Clin Cancer Res June 1 1996 2 (6) 1083-1086;

Main menu

User menu

Search

Table of Contents

Articles

Info for

About Clinical Cancer Research